Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in
NPM1
mutated acute myeloid leukemia
Oncotarget
.
2019 Jan 15;10(5):617.
doi: 10.18632/oncotarget.26610.
Authors
Nikhil Patkar
1
,
Rohan Kodgule
1
2
,
Chinmayee Kakirde
1
,
Goutham Raval
1
,
Prasanna Bhanshe
1
,
Swapnali Joshi
1
,
Shruti Chaudhary
1
,
Y Badrinath
1
,
Sitaram Ghoghale
1
,
Shraddha Kadechkar
1
,
Syed Hasan Khizer
3
,
Sadhana Kannan
4
,
Dhanalaxmi Shetty
5
,
Anant Gokarn
3
,
Sachin Punatkar
3
,
Hasmukh Jain
3
,
Bhausaheb Bagal
3
,
Hari Menon
6
,
Manju Sengar
3
,
Navin Khattry
3
,
Prashant Tembhare
1
,
Papagudi Subramanian
1
,
Sumeet Gujral
1
Affiliations
1
Haematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
2
Homi Bhabha National Institute, Training School Complex, Mumbai, India.
3
Adult Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India.
4
Biostatistics, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
5
Dept of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
6
Haemato-Oncology, CyteCare Cancer Hospital, Bangalore, India.
PMID:
30728913
PMCID:
PMC6355171
DOI:
10.18632/oncotarget.26610
Abstract
[This corrects the article DOI: 10.18632/oncotarget.26400.].
Publication types
Published Erratum